$0.54
Vaxart
Performance
Dividends
1W
1M
YTD
1Y
3Y
7/36
Growth
Score
5/36
Dividend
Score
Valuation
PE Ratio
-2.11
PS Ratio
2.59
RSI
-
0
PEG Ratio
-0.01
0
PRG Ratio
0
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
0
Rule
of 40
-20.28%
0
Gross Margin
16.75%
0
Current Ratio
0.64
Return on Assets
-36.66%
Return on Equity
-91.89%
Return on inv. Capital
-67.05%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 28.70M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -66.95M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 28.70M
2018
2019
2020
2021
2022
2023
2024
6
Events
VXRT
Vaxart
in 108 days
after market close
Earnings per Share is expected with - and revenue with - .
VXRT
Vaxart
in 19 days
after market close
Earnings per Share is expected with -$0.08 +11.11% and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
11.12.1981
MaketCap
122.83M
Country
US
CEO
Steven Lo
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Updated 26.06.2025